09-28 IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026 GL
09-25 US FDA approves Mirum's drug for rare bone disorder RE
09-22 IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026 GL
09-22 Europe Is Losing the Pharma Investment Race — But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi PU
09-21 Ipsen Shares Fall After Early Launch of U.S. Generic Rival DJ
09-21 The arrival of a generic rival to Somatuline rattles Ipsen Zonebourse
09-18 Ipsen Announces Board and Committee Changes CI
09-18 Ipsen appoints Mariette Finet to its Board of Directors GL
09-18 AlphaValue/Baader Europe Ups Price Target, Forecasts for Ipsen on 'Solid' H1 Performance MT
09-17 Ipsen: Incorporating solid H1 operational performance + guidance upgrade Alphavalue
09-17 Ipsen extends its pullback despite AlphaValue Zonebourse
09-15 IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026 AQ
09-14 IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026 GL
09-12 Health Care Flat as Traders Rotate Back Into Fuel-Sensitive Sectors - Health Care Roundup DJ
09-07 IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026 GL
08-31 IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026 GL
08-24 IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026 GL
08-21 Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc. CI
08-21 Ipsen Wraps Up Purchase of US-based Kartos Therapeutics MT
08-21 Ipsen closes the acquisition of Kartos Therapeutics Zonebourse
08-21 Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline GL
08-17 IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026 GL
08-17 Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating MT
08-10 IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026 GL
08-04 Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration CI
No results match your criteria